GSK1437173A Group vs Placebo Group: Number of Subjects With Fatal SAEs
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.027 | 0.0236 | 0.0309 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0287 | 0.0252 | 0.0326 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00163 | -0.00685 | 0.00358 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.943 | 0.782 | 1.14 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.941 | 0.777 | 1.14 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on GSK1437173A Group than on Placebo Group | 612 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | GSK1437173A Group | Subjects received herpes zoster subunit vaccine (gE/AS01B vaccine: GSK1437173A) according to a 0, 2-month schedule. | 208 | 7,695 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo Group | Subjects received saline solution (NaCl solution) as control according to a 0, 2-month schedule. | 221 | 7,710 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Subjects With Fatal SAEs | ClinicalTrials.gov |
| Description | Number of subjects with fatal SAEs during the entire study period were tabulated | ClinicalTrials.gov |
| Time frame | During the entire study period (3 to 5 years following day 0) | ClinicalTrials.gov |
| Population | This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older | ClinicalTrials.gov |
| NCT number | NCT01165177 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Herpes Zoster | ClinicalTrials.gov |
| Interventions | Herpes Zoster Vaccine GSK1437173A, Placebo | ClinicalTrials.gov |
| Lead sponsor | GlaxoSmithKline | ClinicalTrials.gov |
| Results first posted | 2017-05-01 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01165177?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.